Teva : Japan Approves AJOVY Injection For Preventive Treatment Of Migraine In Adults

Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday that Japan's Ministry of Health, Labour and Welfare has approved the use of AJOVY or fremanezumab injection for the preventive treatment of migraine in adults.

AJOVY is a long-acting anti-CGRP subcutaneous injection that is designed for the preventive treatment of migraine and offers both quarterly and monthly dosing options.

AJOVY was developed in Japan by Otsuka Pharmaceutical Co., Ltd. with the assistance and cooperation of Teva as part of a May 2017 exclusive license agreement.

AJOVY is available as a 225 mg/1.5 mL single dose injection in a prefilled syringe or autoinjector with two dosing options - 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT